Klaus Seppi and Marina Peball (Innsbruck Medical University, Innsbruck, Austria) both kindly joined touchNEUROLOGY to share the promising results from their presentation entitled: Effects of Nabilone on Non-motor Symptoms of Parkinson’s Disease – A Randomised Placebo-controlled Study (The NMS-Nab Study). ClinicalTrials.gov identifier: NCT03769896.
1. Could you give us a brief overview of non-motor symptoms in Parkinson’s disease (PD) and the unmet needs in their management? (0:06)
2. What is the rationale for the use of nabilone for the treatment of non-motor symptoms in PD? (0:54)
3. Could you tell us about the NMS-Nab study and its findings? (2:30)
4. Which patients are likely to respond best to nabilone and in whom should it be used with caution? (4:10)
5. What are the implications for these findings or the future investigation of cannabinoids, and what future studies are planned? (4:33)
Disclosures: Klaus Seppi reports receiving personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Grünenthal and Abbvie, honoraria from the International Parkinson and Movement Disorders Society, research grants from FWF Austrian Science Fund, Michael J. Fox Foundation, and International Parkinson and Movement Disorder Society. Marina Peball reports receiving travel compensation for presentation of the study data after study end from AOP Orphan Pharmaceuticals AG, which manufactures the drug that is tested in this study.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!